Online citations, reference lists, and bibliographies.

Cytoreductive Surgery In Ovarian Cancer

C. Pomel, A. Jeyarajah, D. Oram, J. Shepherd, D. Milliken, J. Dauplat, K. Reynolds
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract As the overall prognosis for patients with ovarian cancer is poor, the management of this condition should be restricted to expert multi-disciplinary teams in gynaecological oncology. Apparent early stage ovarian cancer requires accurate and complete staging so that potential sites for metastases are not missed. Omitting adequate staging may have significant consequences including a negative impact on survival rates in young patients. The challenge with advanced ovarian cancer is to obtain a detailed appreciation of the extent of disease. This information allows treatment with primary chemotherapy if the cancer is considered to be inoperable and/or the general condition of the patient renders her unfit for appropriate surgery. Available data would suggest that a 5-year survival rate of 50% is only possible for those patients who have had complete cytoreduction of all tumour. Therefore, the best surgical option for patients with advanced ovarian cancer is a ‘complete’ primary surgical procedure that achieves complete clearance of the abdominal cavity rather than ‘optimal’ surgery that leaves tumour nodules up to 1 cm in diameter in situ in the patient.
This paper references
10.1055/s-2008-1026343
[The surgical treatment of ovarian cancer].
E. Burghardt (1987)
10.1046/j.1525-1438.7.s1.3.x
Prognostic factors in advanced ovarian cancer
A. Cervantes (1997)
10.1016/S1072-7515(03)00234-5
Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications.
P. Morice (2003)
10.1016/J.YGYNO.2007.03.012
Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer: A meta-analysis
R. E. Bristow (2007)
Secondary cytoreductive surgery in ovarian cancer.
G. Michel (1989)
10.1200/JCO.1986.4.6.965
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
P. Conte (1986)
10.1016/0090-8258(92)90107-T
The impact of subspecialty training on the management of advanced ovarian cancer.
S. Eisenkop (1992)
10.1200/JCO.2005.02.1287
Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial.
S. C. Crawford (2005)
10.1200/JCO.2006.07.7800
Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.
A. Axtell (2007)
10.1016/S0140-6736(88)90640-X
FAILURE OF SECOND-LOOK LAPAROTOMY TO INFLUENCE SURVIVAL IN EPITHELIAL OVARIAN CANCER
D. Luesley (1988)
Evaluation of cytoreductive surgery with lymphadenectomy including para-aortic nodes for advanced ovarian cancer.
J. Kigawa (1993)
10.1186/1477-7800-2-3
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
Rhonda L Harmon (2005)
Cytoreduction of ovarian cancer with the Cavitron ultrasonic surgical aspirator.
M. Adelson (1988)
10.1016/S0090-8258(03)00278-6
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.
S. Eisenkop (2003)
10.1016/J.YGYNO.2004.01.029
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
D. Chi (2004)
10.1016/0090-8258(88)90298-3
Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA)--a preliminary report.
M. Deppe (1988)
10.1016/J.YGYNO.2004.11.031
Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study.
A. Fagotti (2005)
10.1038/sj.bjc.6603803
The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13 918 patients
J. Chan (2007)
National survey of ovarian carcinoma. I. A patient care evaluation study of the American College of Surgeons.
H. Averette (1993)
Ovarian cancer staging: does it require a gynecologic oncologist?
W. M. Rich (1993)
10.1016/S1040-1741(08)79160-7
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
J. Thigpen (2008)
The role of appendicectomy in surgical procedure for ovarian cancer
R Fontanelli (1992)
10.1006/gyno.1995.1123
Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer.
J. Fanning (1995)
10.1056/NEJM199601043340101
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
W. Mcguire (1996)
10.1006/gyno.1995.1061
Cytoreductive Surgery in Advanced Epithelial Cancer of the Ovary: The Impact of Aortic and Pelvic Lymphadenectomy
N. Spirtos (1995)
10.1056/NEJM199503093321002
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer.
M. V. D. van der Burg (1995)
10.1016/J.YGYNO.2006.07.045
Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?
G. Aletti (2007)
10.1002/1098-2388(200007/08)19:1<36::AID-SSU6>3.0.CO;2-E
Surgical staging of early invasive epithelial ovarian tumors.
E. Leblanc (2000)
10.1200/JCO.20.5.1248
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
R. Bristow (2002)
10.1200/jco.1988.6.6.983
The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
M. Piver (1988)
Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma.
Griffiths Ct (1975)
Primary Cytoreductive Surgery for Epithelial Ovarian Cancer
N. Hacker (1983)
10.1016/J.YGYNO.2007.02.026
Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
P. Wimberger (2007)
10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO;2-I
Cis‐platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens
S. Vogl (1983)
10.1111/J.1525-1438.2006.00323.X
Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer
X. Deffieux (2006)
10.1200/JCO.2005.03.065
Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
A. Gadducci (2005)
10.1200/JCO.1993.11.1.166
Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma.
B. E. Nelson (1993)
10.1097/00006254-199102000-00020
Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials.
R. Young (1990)
10.1016/0090-8258(92)90100-W
The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study.
W. Hoskins (1992)
10.1111/j.1471-0528.1985.tb01359.x
The role of cytoreductive surgery in advanced carcinoma of the ovary: an analysis of primary and second surgery
E. Wiltshaw (1985)
10.1093/JNCI/DJI102
Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
P. Panici (2005)
[Management of malignant epithelial tumors of the ovary].
C. Pomel (2004)
10.1016/S0002-9378(94)70090-7
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.
W. Hoskins (1994)
Epithelial ovarian cancer. Practical gynecologic oncology
JS Berek (1988)
10.1016/0002-9378(92)91345-B
The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer
P. Rose (1992)
10.1111/j.1471-0528.1968.tb02901.x
A RADICAL OPERATION FOR FIXED OVARIAN TUMOURS
C. Hudson (1968)
10.1046/J.1525-1438.2000.00053.X
Value of lymph node assessment in ovarian cancer: Status of the art at the end of the second millennium
F. Di Re (2000)
10.1016/0002-9378(86)90817-3
Pelvic lymphadenectomy in operative treatment of ovarian cancer
E. Burghardt (1986)
10.1038/sj.bjc.6603323
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis
A. Maggioni (2006)
10.1016/S0140-6736(06)68671-6
Surgery for ovarian cancer: how to improve survival
R. Bristow (2006)
10.1002/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO;2-U
Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
F. Jänicke (1992)
10.1093/JNCI/95.2.113
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
J. Trimbos (2003)
10.1002/1097-0142(19880615)61:12<2571::AID-CNCR2820611231>3.0.CO;2-O
Second‐look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration
S. Lippman (1988)
THE EFFECT OF DEBULKING SURGERY AFTER INDUCTION CHEMOTHERAPY ON THE PROGNOSIS IN ADVANCED EPITHELIAL OVARIAN CANCER
Aria (2001)
10.1016/S0140-6736(84)90594-4
RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA
J. Neijt (1984)



This paper is referenced by
10.4172/1747-0862.1000220
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS+HIPEC) for Recurrent Epithelial Ovarian Cancer (EOC): Indian Experience
S. P. Somashekhar (2016)
10.1097/IGC.0000000000000832
Total Infragastric Omentectomy Including the Vascular Perigastric Arcade in Patients With Advanced Serous Ovarian Tumors.
Gloria Cordeiro Vidal (2017)
Leczenie chirurgiczne w zaawansowanym raku jajnika
Łukasz Wicherek (2012)
Women's health and wellness
Nancy Liskar (2013)
Surgery for ovarian cancer – is it a job for the generalist ? Point of view Surgery for ovarian cancer – is it a job for the generalist ?
Nalinda Silva (2010)
10.1111/J.1525-1438.2006.00580.X
Long‐term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures
A. Tentes (2006)
10.15557/cgo.2013.0012
Modified posterior exenteration in ovarian cancer treatment
Łukasz Wicherek (2013)
10.1097/MD.0000000000014929
Preoperative colonoscopy in patients with a supposed primary ovarian cancer
Renata Raś (2019)
10.1155/2012/358341
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
Antonios-Apostolos K Tentes (2012)
An investigation into the anti-tumour properties of resveratrol against ovarian cancer using the CAM model.
Melanie Gabrielle Singh (2019)
10.4038/SLJOG.V32I3.3987
Surgery for ovarian cancer - is it a job for the generalist?
Samanthi Premaratne (2012)
[Third National Ovarian Consensus. 2011. Grupo de Investigación en Cáncer de Ovario y Tumores Ginecológicos de México "GICOM"].
D. Gallardo-Rincón (2011)
10.1016/B978-2-294-72937-9.00017-6
Chapitre 17 – Techniques et indications chirurgicales pour les cancers de l'ovaire, de la trompe et du péritoine
J. Dauplat (2013)
EPİTELYAL OVER KANSERİ CERRAHİ TEDAVİSİNDE TOTAL PARİETAL PERİTONEKTOMİ
G. Boyraz (2015)
10.6004/JNCCN.2008.0060
The role of cytoreductive/debulking surgery in ovarian cancer.
M. Wakabayashi (2008)
10.1097/IGC.0b013e31824d836c
Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer
L. Ansaloni (2012)
10.1007/978-1-61779-080-5_15
Isolation and culture of ovarian cancer cells and cell lines.
C. Kurbacher (2011)
Critical care and pain management in patients who have undergone cytoreductive surgery for gynecologic malignancies
A. L. Gouez (2010)
10.1111/j.1525-1438.2007.01034.x
Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo
M. Su (2007)
10.15557/CGO.2013.0012
Przydatnosc zmodyfikowanego wytrzewienia tylnego w leczeniu raka jajnika
Łukasz Wicherek (2013)
10.1097/01.AOG.0000192407.04428.bb
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer
G. Aletti (2006)
10.1016/J.TRIA.2015.10.005
Apatone® induces endometrioid ovarian carcinoma (MDAH 2774) cells to undergo karyolysis and cell death by autoschizis: A potent and safe anticancer treatment
J. Gilloteaux (2015)
10.17863/CAM.44734
Magnetic Resonance imaging of tumour biomarkers in ovarian cancer
S. Deen (2019)
10.1186/s13048-020-00662-3
Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
Tung Tung Tsoi (2020)
Molecular characterization of metastatic ovarian cancer by MALDI imaging mass spectrometry.
Ove Johan Ragnar Gustafsson (2012)
Retrospective Study Comparing Primary Debulking Surgery (PDS) with Adjuvant Chemotherapy vs. Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery (IDS) with Adjuvant Chemotherapy in Advanced Carcinoma Ovary
Mohammad Shadab Alam (2015)
LAPAROSCOPIC CYTOREDUCTION AND SURGICAL STATEMENT IN EARLY STAGE OVARIAN CANCER: CASE REPORT
S. Pais-Costa (2012)
Cáncer de ovario en el Instituto Nacional de Oncología y Radiobiología de Cuba: 2001 a 2005
Juan Edmundo Rodríguez Reigosa (2009)
10.1186/s13048-018-0461-5
CT of ovarian cancer: 3D cinematic rendering for preoperative evaluation
Yi-Ren Jin (2018)
10.1016/j.ejso.2018.12.020
An analysis of the morbidity associated with abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
R. Parikh (2019)
10.5772/48155
Abdominal Advanced Oncologic Surgery
Enrico Maria Pasqual (2012)
Diaphragmatic Surgery in Patients with Advanced-Stage Ovarian Cancer: A Literature Review
Olivia Ionescu (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar